by This is interesting. In addition to the two huge multi center phase III trials of Remdesivir for Covid 19 with estimated completion some time in May 2020, there is a smaller but very large trial in Beijing with estimated completion May 1 2020. The East is Remd ! May Day May Day May Day “Estimated Study Completion Date : May 1, 2020” Finally there is a very large trial in Hubei province with estimation completion date April 27 2020 “Estimated Study Completion Date : April 27, 2020” Also there is expanded access already. This is instead of individual requests or compassionate use. Note that one exclusion criterion is eligibility for a controlled trial — people will have to risk getting placebo, because they are eligible for a trial. I think this is ethical.
Topics:
Robert Waldmann considers the following as important: Healthcare, Hot Topics
This could be interesting, too:
Bill Haskell writes ACA Market Place Subsidies
Angry Bear writes U.S. Defense Spending
Bill Haskell writes Efforts to Curb News Media Free Speech
Angry Bear writes The Pick to Be the “Champions of Public Health?”
This is interesting. In addition to the two huge multi center phase III trials of Remdesivir for Covid 19 with estimated completion some time in May 2020, there is a smaller but very large trial in Beijing with estimated completion May 1 2020. The East is Remd ! May Day May Day May Day
“Estimated Study Completion Date : May 1, 2020”
Finally there is a very large trial in Hubei province with estimation completion date April 27 2020
“Estimated Study Completion Date : April 27, 2020”
Also there is expanded access already. This is instead of individual requests or compassionate use. Note that one exclusion criterion is eligibility for a controlled trial — people will have to risk getting placebo, because they are eligible for a trial.
I think this is ethical. You read it here.
On the other hand, they only have enough Remdesivir for 30,000 patients
we have proactively and rapidly scaled our supply chain. As of late March, using the active ingredient we already had in our inventory, we have increased our supply to more than 30,000 patient courses of remdesivir on hand, assuming a 10-day course of treatment for patients.
The synthesis takes time and requires reagents which are in short supply, so they can’t scale up immediately
Our goal is to produce a total of:
More than 140,000 treatment courses by the end of May 2020
More than 500,000 treatment courses by October 2020
More than 1 million treatment courses by December 2020
Several million treatment courses in 2021, if requiredCapacity Expansion through External Manufacturing
We have supplemented our internal manufacturing with significant additional capacity from multiple manufacturing partners in North America, Europe and Asia. Through these efforts, we believe we have created a manufacturing network capable of producing large volumes of remdesivir at the fastest pace feasible.
I think this is a case for some Defence Production Act_ion.